JP5577246B2 - Ｃ型レクチンを介する免疫 - Google Patents

Ｃ型レクチンを介する免疫 Download PDF

Info

Publication number
JP5577246B2
JP5577246B2 JP2010516587A JP2010516587A JP5577246B2 JP 5577246 B2 JP5577246 B2 JP 5577246B2 JP 2010516587 A JP2010516587 A JP 2010516587A JP 2010516587 A JP2010516587 A JP 2010516587A JP 5577246 B2 JP5577246 B2 JP 5577246B2
Authority
JP
Japan
Prior art keywords
clec9a
cells
antigen
fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010516587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534200A (ja
JP2010534200A5 (https=
Inventor
デイヴィッド・サンチョ−マドリッド
オリヴァー・シュルツ
ニール・チャールズ・ロジャース
カエタノ・リース・イー・ソーサ
ダニエル・ペニントン
オリヴァー・ピエール・ジョフレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2010534200A publication Critical patent/JP2010534200A/ja
Publication of JP2010534200A5 publication Critical patent/JP2010534200A5/ja
Application granted granted Critical
Publication of JP5577246B2 publication Critical patent/JP5577246B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
JP2010516587A 2007-07-20 2008-07-21 Ｃ型レクチンを介する免疫 Expired - Fee Related JP5577246B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92999907P 2007-07-20 2007-07-20
US60/929,999 2007-07-20
GBGB0805159.1A GB0805159D0 (en) 2008-03-19 2008-03-19 Immune modulation via C-type lectin
GB0805159.1 2008-03-19
PCT/GB2008/002504 WO2009013484A1 (en) 2007-07-20 2008-07-21 Immune modulation via c-type lectin

Publications (3)

Publication Number Publication Date
JP2010534200A JP2010534200A (ja) 2010-11-04
JP2010534200A5 JP2010534200A5 (https=) 2011-09-08
JP5577246B2 true JP5577246B2 (ja) 2014-08-20

Family

ID=39356783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516587A Expired - Fee Related JP5577246B2 (ja) 2007-07-20 2008-07-21 Ｃ型レクチンを介する免疫

Country Status (13)

Country Link
US (2) US8580266B2 (https=)
EP (1) EP2185586B1 (https=)
JP (1) JP5577246B2 (https=)
CN (1) CN101896500B (https=)
AU (1) AU2008278831B2 (https=)
CA (1) CA2693277A1 (https=)
DK (1) DK2185586T3 (https=)
ES (1) ES2557935T3 (https=)
GB (1) GB0805159D0 (https=)
HR (1) HRP20160033T1 (https=)
HU (1) HUE026387T2 (https=)
SI (1) SI2185586T1 (https=)
WO (1) WO2009013484A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
US20110110861A1 (en) * 2008-05-13 2011-05-12 Mireille Hanna Lahoud Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells
JP2012521199A (ja) * 2009-03-23 2012-09-13 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 免疫応答を調節するための化合物および方法
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
MX2012012833A (es) * 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
WO2013088136A1 (en) 2011-12-12 2013-06-20 Ahrens Susan Ligand for dngr-1 receptor
KR102156616B1 (ko) * 2012-09-26 2020-09-16 쿠크 바이오텍 인코포레이티드 의학적 장치 디자인, 제조 및 시험 시스템
US20160015803A1 (en) * 2014-07-18 2016-01-21 Ross Kedl Immunostimulatory combinations and use thereof
EP3171708B1 (en) * 2014-07-21 2021-03-31 Société des Produits Nestlé S.A. Nutritional products to promote safe swallowing for individuals with dysphagia
CN104789689B (zh) * 2015-05-13 2018-10-02 北京泱深生物信息技术有限公司 作为肺腺癌诊治靶标的clec9a基因
CA2994965A1 (en) * 2015-08-06 2017-02-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for tumor therapy
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN105924501B (zh) * 2016-04-28 2019-04-02 郑州大学 靶向Clec9a的亲和肽WH肽
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
US12091463B2 (en) * 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
JPWO2019244973A1 (ja) * 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
CN113573699A (zh) * 2019-01-08 2021-10-29 乔治亚大学研究基金会 靶向纳米颗粒以及它们的与真菌感染有关的用途
JP7546924B2 (ja) * 2019-03-01 2024-09-09 国立大学法人 筑波大学 アレルギー疾患を処置することに用いるための組成物
CN120590542A (zh) 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
CN111544592B (zh) * 2020-03-13 2022-05-03 中山大学附属第一医院 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
EP3892739A1 (en) * 2020-04-09 2021-10-13 Centre Léon Bérard Type iii interferon for use as a biomarker to predict response to a cancer treatment
GB202011859D0 (en) 2020-07-30 2020-09-16 Francis Crick Institute Ltd Cytosolic delivery
CA3248697A1 (en) 2022-04-21 2023-10-26 The Francis Crick Institute Limited BISPECIFIC LIAISON OFFICERS
EP4558225A1 (en) 2022-07-21 2025-05-28 The Francis Crick Institute Limited Immunoconjugate
GB202401381D0 (en) 2024-02-02 2024-03-20 Francis Crick Institute Ltd Anti-actin antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395872A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
DE10142994A1 (de) * 2001-09-01 2003-03-27 Keiper Gmbh & Co Längseinsteller für einen Fahrzeugsitz
EP1504099A4 (en) * 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES

Also Published As

Publication number Publication date
US20100221265A1 (en) 2010-09-02
US9205153B2 (en) 2015-12-08
WO2009013484A1 (en) 2009-01-29
HRP20160033T1 (hr) 2016-02-26
HUE026387T2 (en) 2016-05-30
JP2010534200A (ja) 2010-11-04
DK2185586T3 (en) 2016-01-18
CA2693277A1 (en) 2009-01-29
CN101896500B (zh) 2015-09-30
SI2185586T1 (sl) 2016-02-29
EP2185586A1 (en) 2010-05-19
GB0805159D0 (en) 2008-04-23
ES2557935T3 (es) 2016-01-29
CN101896500A (zh) 2010-11-24
US8580266B2 (en) 2013-11-12
AU2008278831A1 (en) 2009-01-29
AU2008278831B2 (en) 2013-11-21
US20140328865A1 (en) 2014-11-06
EP2185586B1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
JP5577246B2 (ja) Ｃ型レクチンを介する免疫
US11026973B2 (en) Engineered phagocytic receptor compositions and methods of use thereof
TWI822726B (zh) Ｎｙｅｓｏ ｔ細胞受體
KR102697827B1 (ko) 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
CN114072157A (zh) 工程化的嵌合融合蛋白组合物及其使用方法
Grauer et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma model
KR102748741B1 (ko) 타겟화된 치료학적 면역조절을 위한 mhc 클래스 ib 분자와 펩타이드의 조합
JP2018530331A (ja) 抗原受容体及びその使用
CN110637028A (zh) Hla限制性vcx/y肽和t细胞受体及其用途
CN109072219B (zh) 肿瘤抗原肽
JP2020532300A (ja) がんの処置のためのｂｃｍａおよびｔａｃｉ抗原に特異的な免疫原性ペプチド
JP2020055845A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
JP2020509783A (ja) 抗原受容体及びその使用
JP2023527067A (ja) 免疫調節複合体および治療のためのその使用
CN115087661A (zh) Vcx/y肽及其用途
WO2021100756A1 (ja) 免疫チェックポイント阻害抗体
KR20230147078A (ko) 치료에 사용하기 위한 t 세포
Spadafora Immunogenic properties of differentially activated Dendritic Cells
Hemagglutinin Enhanced Efficacy of Therapeutic Cancer Vaccines Produced
Nguyen et al. The Immune System and Immunotherapy
King Developing DNA fusion gene vaccines: from pre-clinical models to clinical studies
Cozza Host-Conditioning Strategies For Adoptive T Cell Immunotherapy Of Cancer
de Castro Antibody-based vaccines for delivery of antigen to dendritic cells in situ
Nguyen et al. Basic Science of Oncology,(McGraw-Hill International Editions)
HK40015270A (en) Hla-restricted vgll1 peptides and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140707

R150 Certificate of patent or registration of utility model

Ref document number: 5577246

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees